Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Influenza, Human 7Neoplasms 3Waldenstrom Macroglobulinemia 1Vaccine-Preventable Diseases 1Vaccination Hesitancy 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Acceptance of Health Care 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Healthy, no Evidence of Disease 1Health Behavior 1Colorectal Neoplasms 1COVID-19 1Agammaglobulinemia 1

Interventions

Lenalidomide 2plerixafor 1ofatumumab 1SARS-CoV-2 inactivated vaccines 1Influenza Vaccines 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Agammaglobulinemia × Influenza Vaccines × Clear all
NCT01924169 2018-09-20

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Hematologic Diseases, Influenza, Human, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡